Nuvalent jumps after GSK's $10.6 bln acquisition deal
09/06/2026 16:32
BUZZ-Nuvalent jumps after GSK's $10.6 bln acquisition deal Updates
** Shares of cancer drugmaker Nuvalent NUVL.O jump 38.9% to $122.98, snapping a two-day losing streak
** Drugmaker GSK GSK.L agrees to buy NUVL for $10.6 bln
** The all-cash deal values NUVL at $124 per share, a 40% premium to its Monday closing price of $88.49
** Deal is expected to close in the third quarter of 2026
** "We think that NUVL yet again made a good decision in selling to GSK," brokerage Cantor Fitzgerald says
** Barclays says acquisition is "strategically consistent with prior company comments" and "would accelerate GSK entry into the lung cancer space"
** Including session's moves, NUVL up 22.2% YTD
(Reporting by Avinash P and Kunal Das in Bengaluru)